Showing results (1321-1330 of 1,490) with videos related to

Sort By:
Pageof 149
Journal of Medicinal Chemistry|April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted CancersKevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
Cancers|January 22, 2021
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future PerspectivesMichela Roberto, Antonio Astone, Andrea Botticelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancerFrancesco Grossi, Carlo Genova, Lucio Crinò, et al.
Plos One|December 14, 2017
Detection and molecular characterization of the novel recombinant norovirus GII.P16-GII.4 Sydney in southeastern Brazil in 2016Débora Maria Pires Gonçalves Barreira, Túlio Machado Fumian, Marco André Loureiro Tonini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2019
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trialChiara Cremolini, Federica Marmorino, Francesca Bergamo, et al.
The Oncologist|February 20, 2024
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb TrialEmilio Bria, Floriana Morgillo, Marina Chiara Garassino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumorsStefania Uccini, Olga Mannarino, Heather P McDowell, et al.
Melanoma Research|May 17, 2019
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient ProgramSalvador Martin-Algarra, Rebecca Hinshelwood, Soizick Mesnage, et al.
Oncotarget|December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysisDaniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Pageof 149